[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368287-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368287-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","folate-receptor-alpha-for-cancer-therapy-an-antibody-and-antibody-drug-conjugate-target-coming-of-age","Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","","Folate receptor alpha (FRα) is a long-standing therapeutic target in oncology, particularly across ovarian, lung, and subsets of breast cancers, driven by its roles in cellular metabolism and carcinogenesis plus tumor-specific overexpression versus normal tissues. The review consolidates biological significance, expression distribution, and key characteristics of FRα. It surveys the development of FRα-targeting antibodies and antibody-drug conjugates (ADCs), notes the clinical approval of an ovarian cancer ADC, and emphasizes emerging insights from tumor microenvironment, antibody engineering, ADC advances, and combination strategies with chemotherapy, targeted, and immune therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/folate-receptor-alpha-for-cancer-therapy-an-antibody-and-antibody-drug-conjugate-target-coming-of-age/368287/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/folate-receptor-alpha-for-cancer-therapy-an-antibody-and-antibody-drug-conjugate-target-coming-of-age/368287.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is folate receptor alpha (FRα) considered an attractive target for cancer therapy?","Question",{"text":63,"@type":64},"FRα contributes to folate uptake and is involved in cellular metabolism and carcinogenesis. It is also overexpressed in tumors relative to normal tissues, making it a promising therapeutic target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the key folate transporters discussed in the review, and how do they differ?",{"text":68,"@type":64},"The review contrasts RFC and PCFT with folate receptors. RFC transports most dietary THF and antifolates bidirectionally at neutral pH, while PCFT is a high-affinity folate-proton symporter under acidic conditions, mainly in the gastrointestinal tract; folate receptors mediate high-affinity unidirectional uptake via endocytosis.",{"name":70,"@type":61,"acceptedAnswer":71},"How do antibodies and antibody-drug conjugates (ADCs) target FRα, and what is highlighted about clinical development?",{"text":72,"@type":64},"The review discusses ongoing development of FRα-targeting antibodies and ADCs, including that the first approved ADC is for ovarian cancer. It also highlights advances from antibody engineering, tumor microenvironment insights, and combination approaches that may influence future clinical practice.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368287,1790334338,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","REVIEW  \nFolate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age  \nYi Liua, Xinyi Chen a, Theodore Evana, Benjamina Esapaa, Alicia Chenowetha,b, Anthony Cheunga,b, and Sophia N Karagiannis a,b  \naSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King’s College London, Guy’s Hospital, London, UK; bBreast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, Innovation Hub, Guy’s Hospital, London, UK  \nABSTRACT  \nFolate receptor alpha (FRα) has long been the focus of therapeutics development in oncology across several solid tumors, notably ovarian, lung, and subsets of breast cancers. Its multiple roles in cellular metabolism and carcinogenesis and tumor-specific overexpression relative to normal tissues render FRα an attractive target for biological therapies. Here we review the biological significance, expression distribution, and characteristics of FRα as a highly promising and now established therapy target. We discuss the ongoing development of FRα-targeting antibodies and antibody-drug conjugates (ADCs), the first of which has been approved for the treatment of ovarian cancer, providing the impetus for heightened research and therapy development. Novel insights into the tumor microenvironment, advances in antibody engineering to enhance immune-mediated effects, the emergence of ADCs, and several studies of anti-FRα agents combined with chemotherapy, targeted and immune therapy are offering new perspectives and treatment possibilities. Hence, we highlight key translational research and discuss several preclinical studies and clinical trials of interest, with an emphasis on agents and therapy combinations with potential to change future clinical practice.  \nARTICLE HISTORY  \nReceived 31 December 2024 Revised 15 February 2025 Accepted 17 February 2025  \nKEYWORDS  \nADC; antibody; folate receptor alpha; FRα; oncology; targeted therapy  \nIntroduction: overview of folate and folate transporters  \nFolate metabolism plays a key role in human biochemistry that becomes corrupted during tumorigenesis. It plays a central role in one-carbon metabolism, contributing to three fundamental biosynthetic pathways: de novo nucleoside synthesis, methylation reactions, and amino acid production. 1 Due to its key contributions in carcinogenesis, folate metabolism has long been an attractive target in oncology drug development. The first antifolate drug, aminopterin, was among the earliest successful anticancer therapies, and its successor compounds, including methotrexate and pemetrexed, remain in widespread clinical use.2 More recent research has better characterized the mechanisms of folate transport in both normal and malignant tissues. Folate receptor alpha (FRα), a central mediator of folate uptake, has emerged as a uniquely attractive target for anticancer therapy. In this review, we emphasize the clinical potential of exploiting FRα in treatment of cancer, highlighting its growing relevance in advancing precision medicine.  \nFolate, also known as vitamin B9, is an essential nutrient for survival. Inadequate dietary intake can cause anemia and developmental defects.3 Dietary folate lacks biological activity and must be reduced to active tetrahydrofolate (THF) forms, such as 5-methyltetrahydrofolate (5-methyl-THF) and 5-formyltetrahydrofolate (5-formyl-THF) .4 These THF derivatives carry different one-carbon units (i.e., methyl or formyl) which can be used for various cellular biosynthesis  \nprocesses.5 A hydrophilic anionic molecule at physiological pH, folate does not readily diffuse across biological membranes. Uptake into mammalian cells relies on three major folate transporters: the reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT), and folate receptors (FRs) . These proteins are genetically distinct and functionally diverse, but all contribu","cbCaihiOd7NkqHHq","https://ap.wps.com/l/cbCaihiOd7NkqHHq","pdf",2519538,16,"English","# Abstract\n# Introduction: overview of folate and folate transporters\n## Folate metabolism and carcinogenesis\n## Folate transporters: RFC, PCFT, and folate receptors\n## Folate receptor isoforms and focus on FRα","[{\"question\":\"Why is folate receptor alpha (FRα) considered an attractive target for cancer therapy?\",\"answer\":\"FRα contributes to folate uptake and is involved in cellular metabolism and carcinogenesis. It is also overexpressed in tumors relative to normal tissues, making it a promising therapeutic target.\"},{\"question\":\"What are the key folate transporters discussed in the review, and how do they differ?\",\"answer\":\"The review contrasts RFC and PCFT with folate receptors. RFC transports most dietary THF and antifolates bidirectionally at neutral pH, while PCFT is a high-affinity folate-proton symporter under acidic conditions, mainly in the gastrointestinal tract; folate receptors mediate high-affinity unidirectional uptake via endocytosis.\"},{\"question\":\"How do antibodies and antibody-drug conjugates (ADCs) target FRα, and what is highlighted about clinical development?\",\"answer\":\"The review discusses ongoing development of FRα-targeting antibodies and ADCs, including that the first approved ADC is for ovarian cancer. It also highlights advances from antibody engineering, tumor microenvironment insights, and combination approaches that may influence future clinical practice.\"}]","Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age | PDF",1790176034,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/662f4245ef39db3f3cf4ab3bb256af50.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e542e9475b7a665533e326b223038e3.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66d7e365eb2ab49b29d90c5efa1aacb9.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/422c8b3100e1977a8666bf25dd285d3e.webp",980,1276]